Comparison of Outcomes among Chronic Kidney Disease V Patients with COVID-19 at the National Kidney and Transplant Institute: A Retrospective Cohort Study

Table 1

Baseline characteristics of CKD V patients with COVID-19 (n = 436).

	All patients (n = 436) n (%)	HD (n = 298) n (%)	PD (n = 103) n (%)	Dialysis initiation (n = 35) n (%)	value
Age (in years), median	52.5 [IQR:40.5–60]	53 [IQR:41–61]	50 [IQR:33–60]	51 [IQR:43–63]	0.1147^a
≥60 years	123(28)	86(29)	26(25)	11(31)	0.709^b
<60 years	313(72)	212(71)	77(75)	24(69)
Sex
Male	245(56)	167(56)	57(55)	21(60)	0.887^b
Female	191(44)	131(44)	46(45)	14(40)
Primary kidney disease, %yes
DM	146(33)	103(35)	36(35)	7(20)	0.211^b
Hypertension	123(28)	89(30)	27(26)	7(20)	0.413^b
CGN	129(30)	81(27)	35(34)	13(37)	0.254^b
Others	40(9)	27(9)	5(5)	8(23)	0.006^b
Charlson comorbidity index, median	4 [IQR:3–5]	4 [IQR:3–5]	4 [IQR:3–5]	4 [IQR:3–6]	0.5938^a
Chief complaint, %yes
Cough	35(8)	27(9)	5(5)	3(9)	0.397^b
Fever	52(12)	41(14)	7(7)	4(11)	0.170^b
Myalgia	32(7)	22(7)	6(6)	4(11)	0.546^b
Headache	1(1)	1(1)	0	0	1.000^c
Difficulty in breathing	187(43)	143(48)	33(32)	11(31)	0.007^b
Sore throat	0	0	0	0	—
Diarrhoea	11(3)	5(2)	4(4)	2(6)	0.147^c
Nausea	8(2)	5(2)	2(2)	1(3)	0.709^c
Loss of smell/taste	51(12)	22(7)	24(23)	5(14)	<0.0001^b
Others	214(49)	137(46)	58(56)	19(55)	0.158^b
Dialysis duration (in years), median	1 [IQR:0.10–3]	1 [IQR:0.10–3]	0.90 [IQR:0.10–3]	—	0.0689^d
Average net fluid removal per week (in ml), median	5376.5 [IQR:2947–7163]	5722 [IQR:3520–7310]	3790 [IQR:1892–5429]	6410 [IQR:1640–9330]	0.0001^a

^aKruskal–Wallis test was used. Significant results were further analyzed using Dunn’s test; ^bchi-square test was used; ^cFisher’s exact test was used; ^dMann–Whitney U test was used.